However, the use of aggressive drugs in pediatric patients can lead to significant side effects, such as hepatotoxicity, bone marrow suppression, and an increased risk of malignancies—particularly lymphoma, as reported by Diak et al. [19] (2010), who found an incidence of lymphoma four times higher in children treated with TNF inhibitors. The gene discussed is TNF; the disease is lymphoma.